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tachycardia, sinus pauses > 2s, QRS enlargement > 0.12s, hypotension)
didn’tdifferamong patients ageds 600r> 60 yeare, either inptstreated with
PFN (16% and 14% reepactively) or PLA (89’.and 8% respectively). in con-
clusion, the high efficacy of PFN as single oral loading dose in recent-onset
AF without aigns of heari failure is confirmed even in elderly subjects, with a
favorable safety profile. Moreover, conversion to SR after PLA appears to
ooourr leas frequently in elderly patients.
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m1052132 AcuteHemodynamicandRenalEffectsoftheEndothelin-1ReceptorAntagonistTAK-044in
PatientaWithoutHeartFailure
G. Siitaoh, M. Fleisch, X.-W. Yan, R. Wenzel, C. Binggeli, M.C. Bianchetti,
W. Kiowski, T. LOscher.Cardiology Units, University Hospitals of Bem and
ZOffch,Switzedand
Endothelin-1 participates in the regulationof arteriolarand venoustone in
patients (pts) with markedly impaired left ventricular (LV) function and con-
gestive hearf failure (CHF). However, its role in the regulation of vascular
tone in the absence of CHF in not eatabltshed. Accordingly, we tested the
acute effects of single dose, randomized administration of TAK-044 (25, 50
or 100 mg), an endothelin-1 type A and B reoeptor antagonist, or matching
placebo given over 15 minutes intravenously on cardiac and renal hemo-
dynamioe in 24 pte (56 + 6 yeare, 5 females, 19 males) with LV ejection
fraction z 40% and no CHF. Regular medication was discontinued the day
before the study. Renal (pare-aminohippuric acid and inulin clearance) and
cardiac hemodynamice (pulmonary and radial artery catheters, and ECG,
respectively) were determined before and during 4 hours after infusion. Be-
cause there was no clear dose-response relationship, all TAK-044 pts (n =
17)were treated as a group and compared to placebo (n = 7). TAK-044 re-
duced mean arterial (7.6 mmHg), pulmonaty (4 mmHg) aswell as pulmonary
capillary wedged pressures (1.5 mmHg [differences of all measurements vs.
placebo; p < 0.01]). Cardiac index increased (0.25 mUmin/BSA) and hearf
rate and right atrial pressure were,unchanged. Systemic vascular resistance
fell (114dynes.seo.cm-5). Renal plasma flow increased non-significantly and
glomerularfiltration rate was unchanged by TAK-044. Accordingly, renal vas-
cular reSiStSnOSfell (mean 14.1%, p -=0.05) and this change was similar to
that of systemic vascular resistance (mean 22.6%, p < 0.01). Thus, in pts
with no symptoms of CHF, endothelin-1 also contributes to atteriolar tone
and systemic receptor blockade leads to va$cdilation and improves cardiac
index. The lack of influence on right atrial pressure suggests no major effects
on venous tone. Finally, the renal circulation in these pts is not particularly
sensitive to the effects of blockade.
m1052133 N-acetylcysteineImprovesCoronaryVascularEndothelialDysfunction
N.P.Andrews, S. Husain, A. Prasad, M. Husain, R. Mincemoyer,
J.A. Panza, R.O. Cannon, Ill, A.A. Quyyumi. MY, Bethesda, MD, USA
Reduced endothelial nitricoxide(NO) availability in patients (pts)with atheroscle-
rcals may be due to increased breakdown of NO by oxygen free radioala.
Redueed thiola such as N-acetyloysteine (NAC) may improve the bkxwail-
ability of NO by their antioxidant effects or by forming stable adducts of NO.
To investigate whether coronary vascular endothelial dysfunction can be im-
proved byNAC, westudiedtheeffactof intrecoronary NAC(46 mglmin) on the
respcnsea to aoetyloholine (ACh, 30 Kgfmin), sodium nitroprueeide (SNP),
ahd adenoaine in 17 pts with normal Coronav arteries ormildatheroeolerosis
of epicardial mronary arteries. Diameter (D mm) was measured by quantita-
tive angicgraphy, and coronav vascular resistance (R) was estimated using
Doppler flow veicoity.
ACh SNP Adenosine
“/4JR D “%$R D “/6JR D
Control –33 1,9 –8 2.4 -75 2.5
NAC –48 2.1 -42 2.5 -74 2.5
PValue 0.003 0.002 0.006 0.001 0,8 0.8
Intraoorcnary NAC infusion had no effect on resting hemodynamice, but
improved microveacular and epicardial vaacdilation in response to ACh and
SNP, but not to adenosine. The effect of NAC was more pronounced in
pts with depressed response to ACh. Thus, NAC specifically enhances the
effects of endogenous (stimulated by ACh) and exogenous NO (SNP) on the
coronaV vascuiature and may have potential therapeutic value in pts with
endothelial dysfunction.
-~ V.SOdi,atOr~ffeCtS Of f3rSiflNatri.retic Peptide
inCoronaryConductanceandResistance
Arteries
C. Zellner, K. Sudhir, A.A. Protter, E. Ko, S.J. Hutchison, T.-M. Lee,
M.R. Pothireddy,TM. Chou, K. Chatterjee, Univeraityof Ca/ifomia, San
Francism, CA, USA
Brain natriuretic peptide (BNP) is a hormone secreted predominantly by ven-
tricularmyocytes in heart failure, presumably asacompensato~ vascdilatory
mechanism. It has been shown to ameliorate symptoms and EKG abnor-
malities in patients with coronay spasm. BNP-induced vasodilation in vitro
is mediated via increased cGMP, We examined the coronary vaaodilatory
effects of BNP in vivo in 20 anesthetized pigs. Epicardial corona~ cross-
seotionai area (CSA) was measured by intracoronaty ultrasound; average
coronary peak flow velocity (APV) was simultaneously measured by Doppler
velocimet~; and volumetric coronary blood flow (CBF) was calculated. In 14
pigs, intrecoronary BNP (1 pMto O.1KM) induced significant dose-dependent
increases in CSA (12 +3% at 0.1 vM), APV (5 & 4%) and CBF (14+ 6%),
similar in magnitude to intracoronary nitroglycerin 10 vM. The vasodilator re-
sponse was accentuated when the coronary vasculature was preconstrieted
with either endothelin-1 10 nM (increase in CBF: 27 + 6%) or acetylcholine
10 nM. Pre-treatment with the nitric oxide synthase inhibitor nitro-L-arginine
methylester (100 uM) did not inhibit BNP induced vasodilation in epicardial
arteries, but significantly attenuated BNP-induced increase in CBF from 14
* 6% to –3 + S’XO.in another group of pigs (n = 6), pre-treatment with the
cyclooxygenaae inhibitor indomethacin (2 mgkg IV) induced transient eleva-
tions in blood pressure, and significantly attenuated BNP-induced increase
in CSA from 10 + 3Y0to –2 + 3%, We conclude that BNP is a potent epi-
cardia coronary vascdilator, especially in preccnstricted atieries, with less
effects on coronary resistance arteries. This effect may explain BNP-induced
amelioration of coronaty vasospasm. BNP-induced epicardial coronary va-
scdilation may partially be mediated via release of prostaglandins that have
been suggested to influence cGMP in smooth muscle.
[1052-149 I TheEffectofSumatriptanontheHuman
CoronaryCirculation
J. Saucedo-Matar, D.M. Bondie, D.W.M. Muller, SW. Werns. University of
Michigan, Ann Arboc Ml, USA
Previous studies have shown that serotonin is released in the coronary circu-
lation in patients with unstable angina and during PTCA. There areoonflicting
data regarding serotonin receptors in human coronary arteries. Both constric-
tion and dilation of coronary arteries have been observed after stimulation
of 5-hydroxytryptamine (5HT) receptors. This study examined the effect of
a selective 5HTI receptor agonist, sumatriptan, on the corona~ circulation
of 6 patients. Coronaty artery diameter (Diameter) and blood flow (CBF)
were measured after intracoronary acetylcholine (ACh), adenosine (ADO),
and nitroglycerin (NTG), and after intravenous sumatriptan 0.1 mg/min x
30 min. Diameter was measured by computerized quantitative angiography.
CBFwascalculated fmm Diameter andcoronaty flow velocity measured with
a Doppler guidewire.
ACh ADO NTG Sumatriptsn
Diameter +16 +4% +32 &8% +26+ 12% –7 & 60/0
CBF +40l21% +-378& 1160/0 +66 * 377. –17* 7*A
X + SEM exprsssed as percentchange from baseline
Diameter increased after both ACh, an endothelium-dependent vascdila-
tor, and NTG, an endothelium-independent veecdilator. CBF increased after
ACh, ADO, and NTG. Neither Diameter nor CBF increased during suma-
triptan infusion. Thus, intravenous sumatriptan did not dilate epicardial or
resistance coronary arteries despite evidence of preserved endothelium-
dependent and endothelium-independent vasodilation. The results suggest
that 5HTI receptorsare notan important mechanism of ooronaryvasodilation
in the human heart.
11052-150/ fiypOXemia Stimulates ReleaS50f IEndothelin I in
Obstructive Sleep Apnoea Syndrome
M.R. Schulze, F.Schmidt, H. Zhang, J. Niedermeyer, W.G. Daniel.
Depeflment of Cardiolog~ University Clinic Dresden, Germany
Endothelin I (ET 1)and Angiotensin II (AT H)are strong known vascconstric-
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toreandplaya role in heattfailure,coronaryheartdisease,andpulmonary
hypertension(PHT). In vitro studiesshowedthat ET I is releasedfrom
culturedendothelialcellsduringhypoxemia.Obstruefivesleepapnoeasyn-
drome(OSAS)is associatedwith hypoxemiathat altersthe cardiovascular
system.Aimof ourstudywasto provewhetherhypoxemiain manstimulates
releaseof ET L Methods.’In 10 malepatients(pts.;meanage 57.9 + 5.5
y), we meSSUred the circulatingET l-, AT H-,Norepinephrine-(NEPI), and
Epinephrina-(EPI)levelstakenfroman antecubitalveinat 4 occasions:8
pm(Rest)end5 amafterthediagnostic(Diag.)night,and5 amaffertherapy
I (Ther.1)andtherapyII (Ther.11)night.DuringTher.IandIIpts.weretreatad
withCPAP.Respiratorydisturbanceindex(RDI)andoxygendeesturationin-
dex(ODI)weredeterminedduringDiag.,Ther.I andII bypolysomnogrephy.
Resu/fe:ETI andATII weresignificantlyelevatedafterDiag.,anddropped
significantlyafterTher.I and II parallelto a significantdecreaseof RDIand
ODI.NEPIandEPIshowednosignificantchanges.
Rest Diaa. Ther. I Thor. II
RDI n/h 6t.09+21.77 25.93+ 19.t4# 8.33& 8.44~
ODI nfh 57.56 + 23.2S 19.85 + 18.01# 5,19 * 3.635
ET I {pmolfl) 0.98 +0.9S 0673+ 7.16’ 0.88 & 0.76# 0.49+ 0.65$
AT II {nmoljl) 12.48 + 1.49 15.40 + 2.61* 12.98* 1.99# 12.03+ 1.409
values are mesns + SD; “p <0.05 Rest vs Diag.;#p <0.05 Ther. I vs Diag.; 5p <0.05
Ther. II vs Diag.
Conclusion:1. Releaseof ETI istriggeredbyhypoxemiaandATH-levels
areelevatedinpts.withOSAS.2.AdequatetreatmentwithCPAPresultsina
significantdropof ETI andATII Inpts.withOSAS.3. ElevatedET1-andAT
H-levelscouldbemediatorsin thedevelopmentof PHTinpts.withOSAS.
11052-151] PreservedPulmonarvVasodilatorCa~acitvin
~ PatientsWithPrimerj PuimonaryHypsttsnsion
Meaeuredby LoceiVesodiietorApplication
C.Opitz,F.Krackhardt,R.Wensel,G.Baumann,F.X.Kleber.Departmentof
Medicine,Chaiit4,Berlin,Germany
Dueto a variableinfluenceof closingpressureonpulmonatyvascularresis-
tance,the responseof pulmonaryresistancevesselsto variousvasodilators
is bestmeasuredunderstabledrivingpressuresand cardiacoutput.This
wasaccomplishedby meaauringlocalflow velocityin a pulmona~artery
branch.
Weinvestigated10patientswithprimarypulmonawhypertension(mean
pulmonaryarterypressure54* 22rnmHg,meanpulmonatyC=apillavwedge
pressure12* 9 mmHg,pulmonawvascularresistance13+ 8 WoodUnits).
Bioodflow veloeitywas measuredwith a flow wire (0.018”)positioned
in a pulmonaryarterybranchwith a diameterof 3-6 mm as determined
by intravascularultrasound.Drug infusionewereadjustedto providelocal
concentrationsof 10-6-10-4 M Acetylcholine(max.2.5 mglmin),3.12.5-
50.0ng/mi/secProefaglandinEI (max. 8.5 &@kg/min)in the targetvessel,
0.125-1.0@/k@minsodiumnitroprussideand5 mgNifedipintmlus.
Achcauseda significantdose-dependentincreasein bloodflowveioc-
ity withoutmncomitantchangesin pulmonaryor systemichemodynamics
(table).
A flOWVelOCity Responder> 20%) ACardiacoutput
Acarvkholina 12s% i 31%”* 9/10 –0.57 Vmin............
Nlfedipin 56”A+ 1l”A* 5/5 +0.66 Vmin
PGE1 47% * 15% 5/6 +1.12 !Jmin
SNP 31% * 10% 419 +0.50 lrmin
mean + SEM, *p c 0.05, l*p c 0.01
Ourinvestigationdemonstratesapresewadendothelialreceptor-mediated
vasedilatorresponsein patientswithprimarypulmonaryhypertension.This
responseissuperiorto theeffectsof directvasodilatore.
m1052152 Effectaofthe EndotheiinAntegoniatBosentan
afterintravenousAdministrationonCoronary
andSyetemicHemodynamicsin Patientewith
CoronaryArteryDisease
R.R.Wenzel,G.Neil,M. Fleisch,U.Kaufmann,B.Meier,R.Schmitt’,
R.Jones1,M.Clozel T.F.Lk.cher.CardiologyUrriversityHospita/Bem,
Switzerland,1Hoi$mann-LaRoche,Base\,Switzerland
EndothelinplasmaIeveisare elevatedin atherosclerosis,in myocardialin-
farctionand in acutecoronarysyndromes.Toelucidatethe effectsandthe
safetyof endothelinantagonistsin patientswith Coronawarterydisease
(CAD),we performeda double-blind,placebo-controlledrandomizedstudy,
where200mgbosentsnorpiacebowasinfusedintravenouslyover15minin
30patientswithasignifieentstenosisofoneormorecoronaryvessels.Blood
pressure(BP),heatlrate(HR),coronarybloodflow(CBF),coronarydiameter
(CD)beforeand40 minutesafteradministrationof thedrugwereassessed.
CBFwasmeasuredwitha Dopplerguidewire(Flowire”,Cardiometrics)post-
stenotieelly,CDwasassessadbyquantitativecoronayangiogrsphyandBP
wasmeasuredintraarterially(aorta).Corona~flow resewe(CFR)wasas-
sessedwithintrecoronaryadenosine(12or 18#g).
Resuk All patientshadan impairedCFR(< 2.0, n.s.vs placebo).No
seriousadverseeventswereobservedafterinfusionof bosentan;2 ptshada
transient asymptomatic hypotension, 3 patientshadanginapeetoris(1 in the
bosentan-group,2 in the placebo-group).BosentanreducedsystolicBP (p
<0.05 after30rein),whileFreatiratedid notchange.CDtendedto increase
afterbosentan(+0.1+ 0.1 mm,n.s.vs placebo).Despitethe decreasein
blood pressureand the slight increasein CD, CBFdid not changeafter
bosentan(n.s.vscontrol).IncreasesinCDcorrelatedinverselywithplasma
LDL4evels(# = 0.56,p < 0.01),
ConcbsiorxBoeentanis safein patientswithstablecoronaryarterydis-
easeandinspiteof a BPloweringeffecttendsto increaseCBF.Changesin
CDinverselycorrelatewithLDL-cholesterol.Hence,furthertrialswill deter-
minethe effectsof the drugwithprolongedtreatmentand in subgroupsof
CADpatients.
-] kIIprOvedEndoti’teiialFunctionis Associated
withCurrentbutnotPastEstrogenUeein
—
PostmenopausalWomen
L.R.Peterson, M. Courtois, R.Spina,V.G.DWila-Rom6n,S. Barzilai.
WashingtonUnht,St.Louis,MO,USA
Short-termestrogenadminiatrstionimprovesvasomotortoneinpostmenopausal
women,butthevasomotoreffectsofcurrentandpaationg-termoralestrogen
replacementtherapy(ERT)havenotbeanthoroughlystudied.Wetherefore
useda I=er Dopplerdevieeto evaluatemeanforearmcspiliarybloodflowat
baseline,duringa2-minutebrschialocclusion(OCCL),andatpeakbloedflow
duringthe pestleehemichyperemicresponse(HYP)in a totaiof 61 healthy
premenopausal(PREMENO)and postmenopausalwomen.Basellneskin
temperatureand bloodpressuredid not differ in postmenopausalwomen
whohadnevertakenERT(NEVER),thoseon ERTin the past (off ERT>
1 month)(PAST),andthosecurrentlytakinglong-termERT(LONG-TERM).
Forearmcepiilatybloodflow (mean + SD)weeas follows:
Capillay BloodFlow (rluxunits)
n Baseline OCCL HYP
PREMENO 21 13,6+ 3.5 4.6 + 1.1 73.4* we
LONG-TERM 18 17.6+ S.6 3.9 + 1.7 80.9+22.2
NEVER 14 12.9* 3,3 4.1 * 2.0 53.6& 17.0”
PAST 6 13.2+ 4.6 4.4 i 1.5 56.4 k 15.4t
‘p< 0.02; tp <0.001 bothvecsuaLONG-TERM HYP;
Thepeakhyperemicresponsein womenon long-termERTdid notdiffer
from premenopausalwomen.There was a significantdifferencein peak
hyperemicresponseinpostmenopausalwomenonlong-termERTcompsrad
tothatinpostmenopausaiwomenwhohadnevertekenERT.Womenonlong-
termERThada greaterpeakresponsethanthosewho hadtakenit in the
past.Thus,continueduseof long-termoralERTisassoeiatadwithincreaead
endothelialreactivityin postmenopausalwomen:endotheiiaireactivityin
postmenopausalwomenon ERTis notdifferentfromthat in premenopeueai
women,whereasthat in postmenopausalwomenwho had usad ERTbut
stoppadis relativelydecreased.
110~2-1541 Endotheiium-indepandentVasodiiationls
impairedinPatientswithHypercalcemia
T.Neunteufl,R.Katzenschlager,C.Abela,A. Haseen,B. Niaderle,
F.Weidinger,T.Stefenelii.UniversifyofVienna,Austria
Patientswithhypercelcemiareat increasedriskfor prematuredeathfrom
ischemicheartdiseaseand stroke.Moreover,the heart is a target organ
for intactparathyroidhormone(iPTH).Thisstudywasperformedto testthe
Infiuenceof hyperceicemiandelevatediPTHaerumievelsonendetheliurn-
dependent,flow-mediatadvasodilation(FMD)andendothelium-indepandent,
nitroglycerin-inducedilation (NMD).Methods:Twenty-fourpatientswith
PHPT(mean& SD;age55 + 15,serumcaiciurn3.0* 0.3 mmoi/L,iPTH
225* 160pg/mL,serumphosphate0.77+ 0.21mmoVL)andnoevidenceof
coronaryarterydisease(CAD)aswellas30normoealcemicpatientswithout
evidenceof CAD(Non-CAD;age 50 + 13)werestudied.Afterwithdrawal
of all vseoactivemedicationfor at ieast24 h vasodilationfollowingreaetive
hyperemia ndafterO.8mgnitroglycerinwereaeeessadinthebrachiaiattery
by usinghighresolutionultrasound(7 MHz).Re.suk NMDwas impairedin
PHPTptsmmpsredtotheNon-CADcontrols(11.7+ 4.2%vs.15.9& 8.0°4;
p < 0.05).FMDwasnotsignificantlydifferentinPHPTpatientsandNon-CAD
